查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1614031

Dravet 症候群市场：按产品、癫痫类型、严重程度、按最终用户 - 2025-2030 年全球预测

Dravet Syndrome Market by Offering (Diagnosis & Testing Solutions, Dietary Therapies, Medications), Seizure Type (Atonic Seizures, Myoclonic Seizures, Partial seizures), Severity, End-Use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

Dravet 症候群市场价值 2023 年为 6.7647 亿美元，预计到 2024 年将达到 7.3404 亿美元，复合年增长率为 8.70%，到 2030 年将达到 12.1321 亿美元。

Dravet 症候群是一种罕见且具破坏性的癫痫症，始于儿童时期，其特征是频繁、长时间的癫痫发作和发育迟缓。 Dravet 症候群治疗的市场范围包括药物、诊断工具和支持性护理技术。这种需求源于患者复杂且高度未满足的医疗需求，推动了对有效药物和管理解决方案的需求。它的许多用途是抗惊厥药，例如芬氟拉明，以及针对潜在遗传原因的治疗方法。最终用途包括寻求透过创新解决方案优化患者治疗结果的医院、诊所和研究机构。市场成长的关键影响因素包括基因研究的进步、意识的提高以及对鼓励开发和核准新治疗方法的医疗保健政策的支持。对基因治疗和生物製药创新的持续投资带来了潜在的商机。可以透过优先考虑与生物技术公司和学术研究机构建立强有力的伙伴关係关係来利用这些机会，以创造尖端的治疗方法。然而，高昂的研发成本、严格的监管以及可参与临床试验的患者数量的限制等挑战构成了重大障碍。有效应对这些挑战需要对策略联盟和简化监管流程的技术进行投资。此外，创新和研究的理想领域包括寻找候选药物、非侵入性诊断工具和远端医疗解决方案，以增加获得医疗保健的机会。对这个市场的深入了解揭示了其高成长潜力，这主要归功于活跃的研发活动和对有效治疗方法的强烈需求。然而，与现有治疗方法的竞争、某些地区公众意识较低以及报销问题正在阻碍成长。公司可以透过开拓这些创新领域、优化其分销网络以及增加对医疗保健提供者和患者的教育倡议来加速其市场成功。整体而言，Dravet 综合症市场对于敏捷医疗保健公司正面应对多方面挑战具有充足的成长潜力。

主要市场统计
基准年[2023] 67647万美元
预测年份 [2024] 73404万美元
预测年份 [2030] 12.1321亿美元
复合年增长率（%） 8.70%

市场动态：揭示快速发展的 Dravet 症候群市场的关键市场洞察

Dravet 症候群市场正因供需的动态交互作用而转变。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 增加旨在阐明遗传疾病的研发活动
    • 人们对罕见疾病的认识不断增强
    • 为开发药物和治疗 Dravet 症候群的药物提供支持性法规环境
  • 市场限制因素
    • Dravet 症候群相关治疗费用上涨
  • 市场机会
    • Dravet 症候群治疗与药物的基因治疗进展
    • 增加对罕见疾病研究的资助
  • 市场挑战
    • 诊断挑战导致误诊和延误正确诊断

波特的五力：驾驭 Dravet 症候群市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解 Dravet 症候群市场的外部影响

外部宏观环境因素在塑造 Dravet 症候群市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解 Dravet 症候群市场的竞争格局

对 Dravet 综合症市场的详细市场占有率分析可以对供应商的业绩进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

Dravet 症候群市场供应商针对 FPNV 定位矩阵的绩效评估

FPNV 定位矩阵是评估 Dravet 症候群市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了 Dravet 症候群市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对 Dravet 症候群市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告提供了涵盖关键重点领域的市场全面分析：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、未开发地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 增加旨在了解遗传疾病的研究和开发活动
      • 人们对罕见疾病的认识不断增强
      • 支持 Dravet 症候群治疗方法和药物开发的法规环境
    • 抑制因素
      • Dravet 症候群相关治疗费用上涨
    • 机会
      • Dravet 症候群治疗方法与药物基因治疗的进展
      • 增加对罕见疾病研究的资助
    • 任务
      • 诊断挑战会导致误诊和正确诊断的延误。
  • 市场区隔分析
    • 提供者：分发药物来控制癫痫发作并减少癫痫发作频率
    • 最终用途：医院在急诊和管理以及提供专业设备方面的关键作用
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第 6 章 Dravet 症候群市场：透过提供

  • 诊断和测试解决方案
    • 脑电波
    • 基因检测
    • MRI 和电脑断层扫描
  • 饮食疗法
  • 药品
    • Clobazam
    • 司替戊醇
    • 丙戊酸

第 7 章 Dravet 症候群市场：依癫痫类型

  • 失张力发作
  • 肌阵挛发作
  • 局部性发作
  • 光敏性癫痫发作
  • 强直阵挛发作

第 8 章 Dravet 症候群市场：依严重程度

  • 温和的
  • 适度
  • 严重

第 9 章 Dravet 症候群市场：依最终用途

  • 居家护理
  • 医院
  • 专科诊所

第10章美洲Dravet症候群市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章 亚太地区Dravet症候群市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲Dravet症候群市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • STK-001在管理上的突破性功效：临床试验综合分析及未来展望
    • FDA 和 TGA核准将 Encoded Therapeutics 的基因疗法 ETX101 纳入 Dravet 症候群的临床试验
    • 肠脑轴研究取得突破：Bloom Science 的 BL-001 在治疗 Dravet 症候群和 ALS 方面显示出有希望的 1 期试验结果
  • 战略分析和建议

公司名单

  • Biocodex SA
  • Bloom Science, Inc.
  • Cyberonics, Inc.
  • Eisai Co., Ltd.
  • Encoded Therapeutics
  • Epygenix Therapeutics
  • GW Pharmaceuticals by Jazz Pharmaceuticals plc
  • Insys Therapeutics, Inc.
  • Longboard Pharmaceuticals, Inc.
  • OPKO Health Inc.
  • Ovid Therapeutics Inc.
  • PTC Therapeutics
  • Sage Therapeutics
  • Stoke Therapeutics
  • Supernus Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited
  • Virpax Pharmaceuticals
  • Xenon Pharmaceuticals
  • Zogenix Inc by UCB
Product Code: MRR-4D00F1312C81

The Dravet Syndrome Market was valued at USD 676.47 million in 2023, expected to reach USD 734.04 million in 2024, and is projected to grow at a CAGR of 8.70%, to USD 1,213.21 million by 2030.

Dravet Syndrome is a rare, catastrophic form of epilepsy that begins in early childhood, characterized by frequent, prolonged seizures and developmental delays. The market scope for Dravet Syndrome treatment encompasses pharmaceuticals, diagnostic tools, and supportive care technologies. The necessity arises from the complex, high unmet medical needs of patients, driving demand for effective medications and management solutions. Applications mostly revolve around anti-seizure medications like Fenfluramine and therapies targeting the underlying genetic causes. The end-use scope spans hospitals, clinics, and research institutions eager to optimize patient outcomes through innovative solutions. Key influencing factors for market growth include advancements in genetic research, increasing awareness, and supportive healthcare policies that encourage development and approval of novel treatments. The ongoing investments in gene therapy and biopharmaceutical innovations present potential opportunities. These opportunities can be leveraged by prioritizing robust partnerships with biotech firms and academic research entities to create cutting-edge therapies. However, challenges such as high R&D costs, stringent regulatory frameworks, and limited availability of patients for clinical trials pose significant barriers. Navigating these effectively requires strategic collaborations and investment in technologies that streamline regulatory processes. Moreover, the best areas for innovation and research include exploring new drug candidates, non-invasive diagnostic tools, and telemedicine solutions that enhance healthcare accessibility. Insights into this market reveal its high-growth nature, primarily driven by intense R&D activities and a strong demand for effective remedies. Nevertheless, competition from existing treatment options, limited public awareness in some regions, and reimbursement issues are hurdles to growth. Companies can foster market success by tapping into these innovative areas, optimizing distribution networks, and enhancing education initiatives geared towards healthcare providers and patients. Overall, the Dravet Syndrome market presents ample growth potential for agile healthcare companies ready to meet the multifaceted challenges head-on.

KEY MARKET STATISTICS
Base Year [2023] USD 676.47 million
Estimated Year [2024] USD 734.04 million
Forecast Year [2030] USD 1,213.21 million
CAGR (%) 8.70%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Dravet Syndrome Market

The Dravet Syndrome Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increase in research and development activities aimed at understanding genetic disorders
    • Rising awareness of rare diseases
    • Supportive regulatory environments for developments in Dravet syndrome therapies and medications
  • Market Restraints
    • High cost of treatment associated with Dravet syndrome
  • Market Opportunities
    • Advancements in genetic therapy for Dravet syndrome therapies and medications
    • Increased funding for rare disease research
  • Market Challenges
    • Diagnostic challenges leading to misdiagnosis or delays in correct diagnosis

Porter's Five Forces: A Strategic Tool for Navigating the Dravet Syndrome Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Dravet Syndrome Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Dravet Syndrome Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Dravet Syndrome Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Dravet Syndrome Market

A detailed market share analysis in the Dravet Syndrome Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Dravet Syndrome Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Dravet Syndrome Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Dravet Syndrome Market

A strategic analysis of the Dravet Syndrome Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Dravet Syndrome Market, highlighting leading vendors and their innovative profiles. These include Biocodex S.A., Bloom Science, Inc., Cyberonics, Inc., Eisai Co., Ltd., Encoded Therapeutics, Epygenix Therapeutics, GW Pharmaceuticals by Jazz Pharmaceuticals plc, Insys Therapeutics, Inc., Longboard Pharmaceuticals, Inc., OPKO Health Inc., Ovid Therapeutics Inc., PTC Therapeutics, Sage Therapeutics, Stoke Therapeutics, Supernus Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Virpax Pharmaceuticals, Xenon Pharmaceuticals, and Zogenix Inc by UCB.

Market Segmentation & Coverage

This research report categorizes the Dravet Syndrome Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Offering, market is studied across Diagnosis & Testing Solutions, Dietary Therapies, and Medications. The Diagnosis & Testing Solutions is further studied across Electroencephalogram, Genetic Testing, and MRI & CT Scans. The Medications is further studied across Clobazam, Stiripentol, and Valproate.
  • Based on Seizure Type, market is studied across Atonic Seizures, Myoclonic Seizures, Partial seizures, Photosensitive Seizures, and Tonic-Clonic Seizures.
  • Based on Severity, market is studied across Mild, Moderate, and Severe.
  • Based on End-Use, market is studied across Homecare, Hospitals, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increase in research and development activities aimed at understanding genetic disorders
      • 5.1.1.2. Rising awareness of rare diseases
      • 5.1.1.3. Supportive regulatory environments for developments in Dravet syndrome therapies and medications
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment associated with Dravet syndrome
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in genetic therapy for Dravet syndrome therapies and medications
      • 5.1.3.2. Increased funding for rare disease research
    • 5.1.4. Challenges
      • 5.1.4.1. Diagnostic challenges leading to misdiagnosis or delays in correct diagnosis
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Offering: Proliferation of medications to manage & reduce the frequency of seizures
    • 5.2.2. End-Use: Pivotal role of hospitals in treating and managing acute episodes and providing access to specialized equipment
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Dravet Syndrome Market, by Offering

  • 6.1. Introduction
  • 6.2. Diagnosis & Testing Solutions
    • 6.2.1. Electroencephalogram
    • 6.2.2. Genetic Testing
    • 6.2.3. MRI & CT Scans
  • 6.3. Dietary Therapies
  • 6.4. Medications
    • 6.4.1. Clobazam
    • 6.4.2. Stiripentol
    • 6.4.3. Valproate

7. Dravet Syndrome Market, by Seizure Type

  • 7.1. Introduction
  • 7.2. Atonic Seizures
  • 7.3. Myoclonic Seizures
  • 7.4. Partial seizures
  • 7.5. Photosensitive Seizures
  • 7.6. Tonic-Clonic Seizures

8. Dravet Syndrome Market, by Severity

  • 8.1. Introduction
  • 8.2. Mild
  • 8.3. Moderate
  • 8.4. Severe

9. Dravet Syndrome Market, by End-Use

  • 9.1. Introduction
  • 9.2. Homecare
  • 9.3. Hospitals
  • 9.4. Specialty Clinics

10. Americas Dravet Syndrome Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Dravet Syndrome Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Dravet Syndrome Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Breakthrough Efficacy of STK-001 in Dravet Syndrome Management: A Comprehensive Analysis of Clinical Trials and Future Prospects
    • 13.3.2. FDA and TGA Approval Ushers Encoded Therapeutics' Gene Therapy ETX101 into Clinical Trials for Dravet Syndrome
    • 13.3.3. Breakthrough in Gut-Brain Axis Research: Bloom Science's BL-001 Shows Promising Phase 1 Results for Treatment of Dravet Syndrome and ALS
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Biocodex S.A.
  • 2. Bloom Science, Inc.
  • 3. Cyberonics, Inc.
  • 4. Eisai Co., Ltd.
  • 5. Encoded Therapeutics
  • 6. Epygenix Therapeutics
  • 7. GW Pharmaceuticals by Jazz Pharmaceuticals plc
  • 8. Insys Therapeutics, Inc.
  • 9. Longboard Pharmaceuticals, Inc.
  • 10. OPKO Health Inc.
  • 11. Ovid Therapeutics Inc.
  • 12. PTC Therapeutics
  • 13. Sage Therapeutics
  • 14. Stoke Therapeutics
  • 15. Supernus Pharmaceuticals, Inc.
  • 16. Takeda Pharmaceutical Company Limited
  • 17. Virpax Pharmaceuticals
  • 18. Xenon Pharmaceuticals
  • 19. Zogenix Inc by UCB

LIST OF FIGURES

  • FIGURE 1. DRAVET SYNDROME MARKET RESEARCH PROCESS
  • FIGURE 2. DRAVET SYNDROME MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DRAVET SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DRAVET SYNDROME MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL DRAVET SYNDROME MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL DRAVET SYNDROME MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. DRAVET SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. DRAVET SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DRAVET SYNDROME MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DRAVET SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DRAVET SYNDROME MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DRAVET SYNDROME MARKET DYNAMICS
  • TABLE 7. GLOBAL DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ELECTROENCEPHALOGRAM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DRAVET SYNDROME MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DRAVET SYNDROME MARKET SIZE, BY MRI & CT SCANS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DIETARY THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CLOBAZAM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DRAVET SYNDROME MARKET SIZE, BY STIRIPENTOL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DRAVET SYNDROME MARKET SIZE, BY VALPROATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ATONIC SEIZURES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL DRAVET SYNDROME MARKET SIZE, BY MYOCLONIC SEIZURES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL DRAVET SYNDROME MARKET SIZE, BY PARTIAL SEIZURES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL DRAVET SYNDROME MARKET SIZE, BY PHOTOSENSITIVE SEIZURES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL DRAVET SYNDROME MARKET SIZE, BY TONIC-CLONIC SEIZURES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL DRAVET SYNDROME MARKET SIZE, BY MILD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL DRAVET SYNDROME MARKET SIZE, BY MODERATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SEVERE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 61. MEXICO DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 63. MEXICO DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 69. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 70. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 78. AUSTRALIA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 80. AUSTRALIA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. AUSTRALIA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 84. CHINA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 85. CHINA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 86. CHINA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 87. CHINA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. CHINA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 89. CHINA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 90. INDIA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 91. INDIA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 92. INDIA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 93. INDIA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. INDIA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 95. INDIA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 96. INDONESIA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 97. INDONESIA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 98. INDONESIA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 99. INDONESIA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. INDONESIA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 101. INDONESIA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 102. JAPAN DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 103. JAPAN DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 104. JAPAN DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 105. JAPAN DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. JAPAN DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 107. JAPAN DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 108. MALAYSIA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 109. MALAYSIA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 110. MALAYSIA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 111. MALAYSIA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. MALAYSIA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 113. MALAYSIA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 114. PHILIPPINES DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 116. PHILIPPINES DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. PHILIPPINES DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 120. SINGAPORE DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 121. SINGAPORE DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 122. SINGAPORE DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 123. SINGAPORE DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SINGAPORE DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 125. SINGAPORE DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH KOREA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH KOREA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH KOREA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 132. TAIWAN DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 133. TAIWAN DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 134. TAIWAN DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 135. TAIWAN DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. TAIWAN DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 137. TAIWAN DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 138. THAILAND DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 139. THAILAND DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 140. THAILAND DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 141. THAILAND DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. THAILAND DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 143. THAILAND DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 144. VIETNAM DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 145. VIETNAM DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 146. VIETNAM DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 147. VIETNAM DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. VIETNAM DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 149. VIETNAM DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 157. DENMARK DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 158. DENMARK DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 159. DENMARK DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 160. DENMARK DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. DENMARK DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 162. DENMARK DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 163. EGYPT DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 164. EGYPT DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 165. EGYPT DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 166. EGYPT DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. EGYPT DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 168. EGYPT DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 169. FINLAND DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 170. FINLAND DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 171. FINLAND DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 172. FINLAND DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. FINLAND DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 174. FINLAND DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 175. FRANCE DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 176. FRANCE DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 177. FRANCE DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 178. FRANCE DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. FRANCE DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 180. FRANCE DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 181. GERMANY DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 182. GERMANY DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 183. GERMANY DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 184. GERMANY DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. GERMANY DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 186. GERMANY DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 187. ISRAEL DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 188. ISRAEL DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 189. ISRAEL DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 190. ISRAEL DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. ISRAEL DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 192. ISRAEL DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 193. ITALY DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 194. ITALY DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 195. ITALY DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 196. ITALY DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. ITALY DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 198. ITALY DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 199. NETHERLANDS DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 200. NETHERLANDS DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 202. NETHERLANDS DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 204. NETHERLANDS DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 205. NIGERIA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 206. NIGERIA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 207. NIGERIA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 208. NIGERIA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. NIGERIA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 210. NIGERIA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 211. NORWAY DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 212. NORWAY DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 213. NORWAY DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 214. NORWAY DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. NORWAY DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 216. NORWAY DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 217. POLAND DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 218. POLAND DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 219. POLAND DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 220. POLAND DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. POLAND DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 222. POLAND DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 223. QATAR DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 224. QATAR DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 225. QATAR DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 226. QATAR DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. QATAR DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 228. QATAR DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 229. RUSSIA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 230. RUSSIA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 231. RUSSIA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 232. RUSSIA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. RUSSIA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 234. RUSSIA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 235. SAUDI ARABIA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 236. SAUDI ARABIA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 238. SAUDI ARABIA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 240. SAUDI ARABIA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 241. SOUTH AFRICA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH AFRICA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH AFRICA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH AFRICA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 247. SPAIN DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 248. SPAIN DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 249. SPAIN DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 250. SPAIN DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 251. SPAIN DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 252. SPAIN DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 253. SWEDEN DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 254. SWEDEN DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 255. SWEDEN DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 256. SWEDEN DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 257. SWEDEN DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 258. SWEDEN DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 259. SWITZERLAND DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 260. SWITZERLAND DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 262. SWITZERLAND DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 264. SWITZERLAND DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 265. TURKEY DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 266. TURKEY DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 267. TURKEY DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 268. TURKEY DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 269. TURKEY DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 270. TURKEY DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 271. UNITED ARAB EMIRATES DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED KINGDOM DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED KINGDOM DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED KINGDOM DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 282. UNITED KINGDOM DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 283. DRAVET SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 284. DRAVET SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023